These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 24987766)
21. Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance. Reese AC; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB Urology; 2015 Nov; 86(5):991-5. PubMed ID: 26335496 [TBL] [Abstract][Full Text] [Related]
22. Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance. Norman Z; Militza P; Andres F; Daniela F; Alejandro M; Catherine S; Juan F Int Braz J Urol; 2014; 40(2):154-9. PubMed ID: 24856482 [TBL] [Abstract][Full Text] [Related]
23. Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Egevad L Eur Urol; 2009 Feb; 55(2):403. PubMed ID: 18718704 [No Abstract] [Full Text] [Related]
25. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A; Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474 [TBL] [Abstract][Full Text] [Related]
26. Re: Editorial comment on Laparoscopic radical prostatectomy: is intact organ removal attainable? Study of margin status. Schellhammer PF J Urol; 2006 May; 175(5):1963; author reply 1964. PubMed ID: 16600808 [No Abstract] [Full Text] [Related]
27. The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer. Van der Kwast TH Eur Urol; 2012 Sep; 62(3):469-71. PubMed ID: 22521091 [No Abstract] [Full Text] [Related]
33. Editorial Comment to Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy. Mearini L Int J Urol; 2015 Nov; 22(11):1035-6. PubMed ID: 26303376 [No Abstract] [Full Text] [Related]
34. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744 [TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy versus watchful waiting in early prostate cancer. Bill-Axelson A; Holmberg L; Ruutu M; Garmo H; Stark JR; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Steineck G; Adami HO; Johansson JE; N Engl J Med; 2011 May; 364(18):1708-17. PubMed ID: 21542742 [TBL] [Abstract][Full Text] [Related]
36. Early prostate cancer--treat or watch? Klotz L; Thompson I N Engl J Med; 2011 Aug; 365(6):569. PubMed ID: 21830972 [No Abstract] [Full Text] [Related]
37. Editorial comment to robot-assisted or pure laparoscopic nerve-sparing radical prostatectomy: what is the optimal procedure for the surgical margins? A single center experience. Trinh QD Int J Urol; 2012 Dec; 19(12):1082. PubMed ID: 22853176 [No Abstract] [Full Text] [Related]